Biotechnology · Healthcare
Head of Investor Relations
Head of Investor Relations
Biomarin Pharmaceutical Inc (BMRN)Equibles does not estimate personal net worth.
Get an email with a short summary when Biomarin Pharmaceutical Inc publishes a filing, an earnings call transcript or a press release.
Get BMRN alertsTraci McCarty is recorded as Head of Investor Relations at Biomarin Pharmaceutical Inc (BMRN). Traci McCarty has spoken on 26 earnings calls across 1 company, most recently for Biomarin Pharmaceutical Inc on November 2, 2026. Biomarin Pharmaceutical Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Biomarin Pharmaceutical Inc includes Alexander Hardy (CEO and Board Member), Richard A. Meier (Chairman), Brian Mueller (CFO) and 7 others.
“To remind you, this non-confidential presentation contains forward-looking statements about the business prospects of Biomarin Pharmaceutical, Inc., including expectations regarding Biomarin's financial performance, commercial products, and potential future products in different areas of therapeutic research and…”
“To remind you, this non-confidential presentation contains forward-looking statements about the business prospects of BioMarin Pharmaceutical, Inc., including expectations regarding BioMarin's financial performance, commercial products, and potential future products in different areas of therapeutic research and…”
“And starting on slide two, to remind you, this non-confidential presentation contains forward-looking statements about the business prospects of BioMarin Pharmaceutical, Inc., including expectations regarding BioMarin's financial performance, commercial products, and potential future products in different areas of…”
“To remind you, this non-confidential presentation contains forward-looking statements about the business prospects of BioMarin Pharmaceutical, Inc., including expectations regarding BioMarin's financial performance, commercial products, and potential future products in different areas of therapeutic research and…”
Biotechnology · Healthcare
Head of Investor Relations